Melane Sampson, Author at BioTuesdays

Developments

Assembly broadens program into cholestatic liver diseases

Assembly Biosciences (NASDAQ: ASMB) has announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary...

May 22, 2026

Developments

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced that Royal Columbian Hospital (RCH) has dosed its first patient in the ongoing Phase 2 trial evaluating LSALT peptide as a new drug to prevent acute kidney...

May 22, 2026

Developments

Adagio submits PMA for vCLAS Ventricular Ablation System for VT

Adagio Medical Holdings (NASDAQ: ADGM) has announced the submission of its Premarket Approval (PMA) application to the FDA for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent...

May 21, 2026

Developments

Envoy expands IP portfolio with new patents in fully implanted hearing technology

Envoy Medical (NASDAQ: COCH) has announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the company’s intellectual...

May 20, 2026

Developments

CRC approves Cohort 2 opening of nimacimab expansion study

Skye Biosciences (NASDAQ: SKYE) has announced that the Cohort Review Committee (CRC) has approved opening the second cohort of the CBeyond Part C Expansion study of nimacimab in obesity, based on favorable safety data...

May 20, 2026

Developments

PharmaJet spotlights review in Qeios listing advantages of needle-free ID delivery v. traditional needle and syringe

Closely held PharmaJet has highlighted a peer-reviewed publication in the AI-powered open science publishing platform Qeios, which evaluated the evidence on implementation of novel technologies for intradermal (ID)...

May 19, 2026

Executive Moves

Immunic appoints Michael W. Bonney as BoD chair

Immunic (NASDAQ: IMUX) has announced the appointment of biopharmaceutical executive Michael W. Bonney as chair of its board of directors (BoD), effective May 16, 2026. Simona Skerjanec, MPharm, MBA, will transition from...

May 19, 2026

Developments

Defence expands ADC platform with analytical and cellular testing

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has announced the expansion of internal capabilities to execute critical stages of its ACCUM-enabled antibody drug conjugates (ADC) development pipeline. According...

May 19, 2026

Feature

illumiSonics expanding the limits of tissue imaging with a single scan

Closely held illumiSonics is addressing a significant unmet medical need by redefining tissue imaging with its proprietary multi-laser imaging (MLI) platform, an advanced modality designed for life sciences research...

May 19, 2026

Developments

BriaCell expands pipeline to ovarian cancer candidate

BriaCell Therapeutics (NASDAQ: BCTX, BCTXL; TSX: BCT) has announced progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. According to the...

May 15, 2026

Author - Melane Sampson

Assembly broadens program into cholestatic liver diseases

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Adagio submits PMA for vCLAS Ventricular Ablation System for VT

Envoy expands IP portfolio with new patents in fully implanted hearing technology

CRC approves Cohort 2 opening of nimacimab expansion study

PharmaJet spotlights review in Qeios listing advantages of needle-free ID delivery v. traditional needle and syringe

Immunic appoints Michael W. Bonney as BoD chair

Defence expands ADC platform with analytical and cellular testing

illumiSonics expanding the limits of tissue imaging with a single scan

BriaCell expands pipeline to ovarian cancer candidate

Subscribe